Keyphrases
Clinical Trials
100%
Treatment Burden
100%
Patient Benefit
100%
Cabozantinib
100%
Drug Development
50%
Single-arm Trial
50%
Adverse Event Rates
50%
PubMed
25%
MEDLINE
25%
Embase
25%
Trial Design
25%
Cochrane
25%
Conflicting Results
25%
Cross-sectional Review
25%
Cancer Treatment
25%
Drug Efficacy
25%
Trial Characteristics
25%
Risk Profile
25%
Objective Response Rate
25%
Cumulative Risk
25%
Median Overall Survival
25%
Clinical Benefit
25%
Interventional Clinical Trials
25%
Survival Median
25%
Solid Cancer
25%
Survival Response
25%
Clinical Trial Participant
25%
Median Progression-free Survival
25%
Trial Efficiency
25%
Participant Safety
25%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Cabozantinib
100%
Adverse Event
50%
Malignant Neoplasm
50%
Drug Development
50%
Progression Free Survival
25%
Overall Survival
25%